Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Medical supply

The NHS and ABPI at 70: inching closer to the triple win

The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...

- PMLiVE

Daily Brief: Immunotherapy combos dominate ASCO, Pharma’s Brexit warning, Big data and prostate cancer

News from the frontline of pharma, biotech and healthcare

- PMLiVE

Pharma and biotech leaders back ’no deal’ Brexit warning

Ongoing division in Conservative party means 'no deal' remains a possibility

- PMLiVE

Daily Brief:  Calls for early Brexit deal for science and innovation, Gottlieb threatens to name and shame

A rapid round up of news from pharma, biotech and healthcare

- PMLiVE

Daily Brief: Deal done, Takeda to cut $1.4bn, Brexit latest, Valeant rebrands

A rapid round-up of the top pharma, biotech and healthcare news

- PMLiVE

Morning brief: Roche raises outlook for 2018, ASCO abstracts revealed and more

A rapid round up of pharma, biotech and healthcare news

Shire Basingstoke

Morning brief: Takeda closes in on $64bn merger, GSK unveils team, and more

A rapid run-down of news in pharma, biotech and healthcare

Uncertainty, austerity and Brexit

What does it mean for the life science sector?

Brexit Means Brexit

The differential destinations of post-Brexit pharma

Sanofi reception

Sanofi’s PD-1 inhibitor starts EU review for skin cancer

Cemiplimab could be the first PD-1-targeting drug approved for CSCC

- PMLiVE

Takeda’s Alofisel becomes Europe’s first allogeneic stem cell therapy

Will treat perianal fistulas in adult patients with Crohn’s disease

- PMLiVE

AZ finally gets EU nod for Veltassa rival Lokelma

And expects a US FDA verdict for the hyperkalaemia treatment later this year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links